April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Regulation Of Immune Response In Post-operative Endophthalmitis
Author Affiliations & Notes
  • Arnaud Sauer
    Ophthalmology,
    Strasbourg University Hospital, Strasbourg, France
  • Gilles Prevost
    Bacteriology,
    Strasbourg University Hospital, Strasbourg, France
  • Christophe Chiquet
    Ophthalmology, Grenoble University Hospital, Grenoble, France
  • Catherine P. Garcher
    Ophthalmology, University Hospital, Dijon, France
  • Jean-Paul Berrod
    Ophthalmology, Nancy University Hospital, Nancy, France
  • Alain M. Bron
    Ophthalmology, University Hospital, Dijon, France
  • Odile Villard
    Parasitology,
    Strasbourg University Hospital, Strasbourg, France
  • Claude Speeg-Schatz
    Ophthalmology,
    Strasbourg University Hospital, Strasbourg, France
  • Ermanno Candolfi
    Institut de Parasitologie, Strasbourg, France
  • Tristan Bourcier
    Ophthalmology, University Hospital of Strasburg, Strasbourg, France
  • Footnotes
    Commercial Relationships  Arnaud Sauer, None; Gilles Prevost, None; Christophe Chiquet, None; Catherine P. Garcher, None; Jean-Paul Berrod, None; Alain M. Bron, None; Odile Villard, None; Claude Speeg-Schatz, None; Ermanno Candolfi, None; Tristan Bourcier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5623. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arnaud Sauer, Gilles Prevost, Christophe Chiquet, Catherine P. Garcher, Jean-Paul Berrod, Alain M. Bron, Odile Villard, Claude Speeg-Schatz, Ermanno Candolfi, Tristan Bourcier; Regulation Of Immune Response In Post-operative Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5623.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Endophthalmitis is the most feared complication of all ophthalmologic surgeries. Taking into account the opposing needs of limiting pathogen multiplication and minimizing tissue destruction, both antibiotics and anti-inflammatory drugs are needed for endophthalmitis care. The aim of our study is to study the immune response in aqueous humor of infected patients.

Methods: : In a prospective and multicenter study, aqueous humors of patients with endophthalmitis and control (cataract surgery) were collected. Multiplex immunoassay (Bioplex*) was done in order to define cytokines patterns. Twenty-seven cytokines, chemokines and growth factors were studied. Two-way ANOVA test was realized for each inflammatory marker to determine any difference between infected and control patients.

Results: : Aqueous humor was sampled in 24 patients with endophthalmitis and 88 controls. Endophthalmitis was leading to high levels of cytokines and chemokines of the Th1 (Interleukin (IL)-2, IL-15, IFN-γ, TNF-α, IL-7, G-CSF, MCP-1, IL-8, IP-10) and Th17 (IL-17, IL-6, IL-1b) ways (p < 0,0001). To the contrary, Treg markers (IL-10, IL-27) were not increased. Moreover, very high levels of VEGF and FGF were noted in aqueous humors of patients with endophthalmitis as compared to the control (p < 0,0001).

Conclusions: : Th1 and Th17 cells may play an important anti-infectious role in modulating pathogen proliferation in infected eyes, and repressing Treg cells. But this huge inflammatory response may be responsible for retinal destruction as a collateral effect. Moreover, pro-angiogenic factors are secreted in infected eyes. Antagonism of TH17 by Tregs cells and anti-angiogenic drugs could be a way to limit ocular lesion and may open new therapeutic approach by stimulating Tregs cells or repressing TH17 cells.

Keywords: endophthalmitis • inflammation • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×